Shares of Vir Biotechnology, Inc. (VIR) soared 6.24% in pre-market trading on Thursday, despite the company reporting a quarterly loss. The biotechnology firm's stock movement comes in the wake of its first-quarter earnings release, which revealed mixed results but maintained strong analyst support.

Vir Biotechnology reported a quarterly adjusted loss of 88 cents per share, slightly wider than the mean analyst expectation of a 84 cents per share loss. While this missed estimates, it showed an improvement from the 48 cents per share loss reported in the same quarter last year. Revenue for the quarter fell 94.6% to $3.03 million, falling short of the $8.59 million analysts had expected.

Despite the earnings miss, several factors appear to be driving investor optimism. Analysts maintain a positive outlook on Vir Biotechnology, with the current average rating being "buy". Out of the analysts covering the stock, 7 recommend either "strong buy" or "buy", while 2 suggest "hold". Additionally, the mean earnings estimate has risen by about 3.5% over the last three months, with no negative revisions in the past 30 days. This sustained confidence from analysts, coupled with a median 12-month price target of $20.00, may be contributing to the stock's pre-market rally.

The surge also comes after a period of significant decline, with Vir Biotechnology shares having fallen 13.4% this quarter and 23.6% year-to-date prior to today's movement. This suggests that investors may view the current price levels as an attractive entry point, especially given the maintained analyst optimism despite the challenging quarter.